File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Long-term beneficial outcome of Chinese asymptomatic patients with HBeAg-positive chronic hepatitis B on continuous lamivudine therapy: 7-year experience

TitleLong-term beneficial outcome of Chinese asymptomatic patients with HBeAg-positive chronic hepatitis B on continuous lamivudine therapy: 7-year experience
Authors
Issue Date2005
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The 56th Annual Meeting and Postgraduate Course of the American Association of Liver Diseases (AASLD), San Francisco, CA., 11-15 November 2005. In Hepatology, 2005, v. 42 suppl. S1, p. 583A, abstract no. 985 How to Cite?
AbstractAIM: To determine whether long-term lamivudine treatment in asymptomatic patients can reduce the risk of hepatocellular carcinoma (HCC) and cirrhosis-related complications. Patients and METHOD: Two hundred and sixty-six HBeAg-positive patients (140 with lamivudine and 126 without treatment serving as controls) were recruited from the Hepatitis Clinic, Queen Mary Hospital, Hong Kong. They included all patients who participated in 3 controlled trials of lamivudine (NUCB 3009, 3018, 4003) and all the other patients who fulfilled the inclusion criteria but were not included in the trials seen at the same period of time (1994-1997). All lamivudine-treated patients were maintained on lamivudine throughout follow-up irrespective of HBeAg seroconversion. RESULTS: There were no differences in the baseline characteristics and liver biochemistry between the 140 treated patients (M:F 105:35; median age 33.9 years) and the 126 controls (M:F 92:34; median age 33.3 years). The follow-up duration was significantly longer in controls compared to that of lamivudine-treated patients (median 106.2 vs. 90 months respectively, p0.004). There were no differences in the cumulative rates of HBeAg seroconversion and hepatitis flare between the two groups (pNS). However lamivudine-treated patients had a slower decline in albumin levels during the follow-up period compared to controls (median drop 3 vs. 4 g/L respectively, p0.025). 93 (66.4%) lamivudine-treated patients and 81 (64.3%) controls had normal ALT level at the last follow-up. HCC occurred in 1 lamivudine-treated patient and 3 controls. Cirrhosis developed in 6 lamivudine-treated patients and 15 controls. Using Kaplan-Meier analysis, lamivudine-treated patients had a significantly lower cumulative risk of development of complications compared to controls (log rank test, p0.035). At the time of writing, YMDD mutations were determined in 38 lamivudine-treated patients with elevated transaminases during follow-up. 36 had YMDD mutations. At the last follow-up, there were no differences in the liver biochemistry between patients with YMDD mutations and controls; 24 (66.7%) of patients with YMDD mutations had normal ALT levels. CONCLUSIONS: Long-term lamivudine treatment can reduce the risk of complications from CHB in asymptomatic HBeAg-positive patients. Development of YMDD mutations was not associated with more serious disease when compared to untreated patients.
Persistent Identifierhttp://hdl.handle.net/10722/101189
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752

 

DC FieldValueLanguage
dc.contributor.authorYuen, RMFen_HK
dc.contributor.authorSeto, WKen_HK
dc.contributor.authorChow, DHFen_HK
dc.contributor.authorTsui, Ken_HK
dc.contributor.authorWong, DKHen_HK
dc.contributor.authorChan, Pen_HK
dc.contributor.authorBut, Den_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-25T19:39:31Z-
dc.date.available2010-09-25T19:39:31Z-
dc.date.issued2005en_HK
dc.identifier.citationThe 56th Annual Meeting and Postgraduate Course of the American Association of Liver Diseases (AASLD), San Francisco, CA., 11-15 November 2005. In Hepatology, 2005, v. 42 suppl. S1, p. 583A, abstract no. 985en_HK
dc.identifier.issn0270-9139en_HK
dc.identifier.urihttp://hdl.handle.net/10722/101189-
dc.description.abstractAIM: To determine whether long-term lamivudine treatment in asymptomatic patients can reduce the risk of hepatocellular carcinoma (HCC) and cirrhosis-related complications. Patients and METHOD: Two hundred and sixty-six HBeAg-positive patients (140 with lamivudine and 126 without treatment serving as controls) were recruited from the Hepatitis Clinic, Queen Mary Hospital, Hong Kong. They included all patients who participated in 3 controlled trials of lamivudine (NUCB 3009, 3018, 4003) and all the other patients who fulfilled the inclusion criteria but were not included in the trials seen at the same period of time (1994-1997). All lamivudine-treated patients were maintained on lamivudine throughout follow-up irrespective of HBeAg seroconversion. RESULTS: There were no differences in the baseline characteristics and liver biochemistry between the 140 treated patients (M:F 105:35; median age 33.9 years) and the 126 controls (M:F 92:34; median age 33.3 years). The follow-up duration was significantly longer in controls compared to that of lamivudine-treated patients (median 106.2 vs. 90 months respectively, p0.004). There were no differences in the cumulative rates of HBeAg seroconversion and hepatitis flare between the two groups (pNS). However lamivudine-treated patients had a slower decline in albumin levels during the follow-up period compared to controls (median drop 3 vs. 4 g/L respectively, p0.025). 93 (66.4%) lamivudine-treated patients and 81 (64.3%) controls had normal ALT level at the last follow-up. HCC occurred in 1 lamivudine-treated patient and 3 controls. Cirrhosis developed in 6 lamivudine-treated patients and 15 controls. Using Kaplan-Meier analysis, lamivudine-treated patients had a significantly lower cumulative risk of development of complications compared to controls (log rank test, p0.035). At the time of writing, YMDD mutations were determined in 38 lamivudine-treated patients with elevated transaminases during follow-up. 36 had YMDD mutations. At the last follow-up, there were no differences in the liver biochemistry between patients with YMDD mutations and controls; 24 (66.7%) of patients with YMDD mutations had normal ALT levels. CONCLUSIONS: Long-term lamivudine treatment can reduce the risk of complications from CHB in asymptomatic HBeAg-positive patients. Development of YMDD mutations was not associated with more serious disease when compared to untreated patients.-
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_HK
dc.relation.ispartofHepatologyen_HK
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.en_HK
dc.titleLong-term beneficial outcome of Chinese asymptomatic patients with HBeAg-positive chronic hepatitis B on continuous lamivudine therapy: 7-year experienceen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0270-9139&volume=42 &issue=4 Suppl 1&spage=583A&epage=&date=2005&atitle=Long-term+beneficial+outcome+of+Chinese+asymptomatic+patients+with+HBeAg-positive+chronic+hepatitis+B+on+continuous+lamivudine+therapy:+7-year+experience.en_HK
dc.identifier.emailYuen, RMF: mfyuen@hkucc.hku.hken_HK
dc.identifier.emailWong, DKH: danywong@hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, RMF=rp00479en_HK
dc.identifier.authorityWong, DKH=rp00492en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/hep.20926-
dc.identifier.hkuros122572en_HK
dc.identifier.hkuros130903-
dc.identifier.volume42en_HK
dc.identifier.issuesuppl. S1en_HK
dc.identifier.spage583A, abstract no. 985en_HK
dc.identifier.epage583A, abstract no. 985-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats